Published in Cancer Cell on December 01, 2006
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
The essence of senescence. Genes Dev (2010) 8.21
The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol (2010) 7.58
Autophagy mediates the mitotic senescence transition. Genes Dev (2009) 6.80
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov (2011) 4.05
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A (2007) 3.20
The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol (2007) 3.14
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science (2009) 2.51
Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet (2015) 2.43
Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell (2011) 2.40
Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape. Science (2011) 2.12
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest (2010) 1.98
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci U S A (2011) 1.94
Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene (2007) 1.92
Cellular senescence and organismal aging. Mech Ageing Dev (2008) 1.92
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell (2008) 1.88
Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell (2007) 1.87
Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell (2008) 1.86
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev (2007) 1.81
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One (2008) 1.72
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell (2015) 1.70
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle (2011) 1.67
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene (2009) 1.66
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res (2009) 1.65
Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol (2009) 1.64
How does the Schwann cell lineage form tumors in NF1? Glia (2008) 1.63
AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS One (2014) 1.62
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet (2008) 1.57
Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov (2012) 1.57
Cell cycle arrest is not senescence. Aging (Albany NY) (2011) 1.57
BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. Cancer Discov (2016) 1.54
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 1.48
AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene (2011) 1.45
The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med (2009) 1.43
MicroRegulators come of age in senescence. Trends Genet (2011) 1.42
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res (2008) 1.42
Whole Exome Sequencing of Growing and Non-Growing Cutaneous Neurofibromas from a Single Patient with Neurofibromatosis Type 1. PLoS One (2017) 1.39
Cellular senescence controls fibrosis in wound healing. Aging (Albany NY) (2010) 1.36
Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene (2011) 1.32
A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev (2011) 1.30
MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2011) 1.28
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF. J Invest Dermatol (2010) 1.27
SASP reflects senescence. EMBO Rep (2009) 1.27
Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. Mol Cell Biol (2008) 1.23
Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res (2009) 1.19
The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. Aging (Albany NY) (2009) 1.19
A screen of apoptosis and senescence regulatory genes for life span effects when over-expressed in Drosophila. Aging (Albany NY) (2009) 1.14
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol (2012) 1.14
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J Leukoc Biol (2009) 1.10
The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer (2015) 1.09
Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell (2012) 1.09
Construction of a computable network model for DNA damage, autophagy, cell death, and senescence. Bioinform Biol Insights (2013) 1.08
Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res (2007) 1.07
Progeria, rapamycin and normal aging: recent breakthrough. Aging (Albany NY) (2011) 1.06
Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res (2010) 1.05
Unexpected pieces to the senescence puzzle. Cell (2008) 1.04
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood (2009) 1.03
Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res Rev (2008) 1.02
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov (2012) 1.01
p53 and p16(INK4A) independent induction of senescence by chromatin-dependent alteration of S-phase progression. Nat Commun (2011) 1.00
Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev (2014) 1.00
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast (2013) 1.00
Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci U S A (2010) 1.00
Long noncoding RNA PANDA and scaffold-attachment-factor SAFA control senescence entry and exit. Nat Commun (2014) 0.99
NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. J Cell Biol (2015) 0.99
Cellular senescence and cancer chemotherapy resistance. Drug Resist Updat (2012) 0.99
Ras-induced senescence and its physiological relevance in cancer. Curr Cancer Drug Targets (2010) 0.99
Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res (2013) 0.98
A comparison of oncogene-induced senescence and replicative senescence: implications for tumor suppression and aging. Age (Dordr) (2014) 0.98
Regulation of senescence in cancer and aging. J Aging Res (2011) 0.98
Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling. J Invest Dermatol (2010) 0.97
The PI3K/Akt/mTOR pathway is implicated in the premature senescence of primary human endothelial cells exposed to chronic radiation. PLoS One (2013) 0.97
RAS unplugged: negative feedback and oncogene-induced senescence. Cancer Cell (2006) 0.96
The developing story of Sprouty and cancer. Cancer Metastasis Rev (2014) 0.96
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell (2015) 0.96
Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proc Natl Acad Sci U S A (2014) 0.95
Novel ARF/p53-independent senescence pathways in cancer repression. J Mol Med (Berl) (2011) 0.95
Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer (2011) 0.95
Physical and functional interaction between PML and TBX2 in the establishment of cellular senescence. EMBO J (2011) 0.94
The generation of neutrophils in the bone marrow is controlled by autophagy. Cell Death Differ (2014) 0.94
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis (2007) 0.94
BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia (2009) 0.94
Oxidative stress in aging human skin. Biomolecules (2015) 0.94
Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol Cell Biol (2010) 0.93
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell (2005) 12.73
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 7.50
Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev (2000) 5.80
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev (1998) 5.14
Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science (2002) 5.08
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42
Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature (2001) 4.14
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol (2004) 3.80
Repression of c-fos transcription and an altered genetic program in senescent human fibroblasts. Science (1990) 3.69
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol (2004) 3.46
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet (1996) 3.08
Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem (2002) 3.01
Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol (2001) 2.27
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet (1995) 2.11
Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol (2005) 1.94
Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res (1999) 1.86
Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene (1995) 1.78
A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts. Cancer Res (1998) 1.67
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev (2003) 1.64
Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2. Mol Cell Biol (1996) 1.63
SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem (1996) 1.48
Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem (2000) 1.36
Characterisation of cis-acting sequences reveals a biphasic, axon-dependent regulation of Krox20 during Schwann cell development. Development (2002) 1.33
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol (2003) 1.07
Developmental regulation and overexpression of the transcription factor AP-2, a potential regulator of the timing of Schwann cell generation. Eur J Neurosci (2001) 1.00
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell (2002) 3.29
Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol (2005) 3.14
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
TORC1 is essential for NF1-associated malignancies. Curr Biol (2007) 2.08
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev (2003) 1.64
Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res (2006) 1.59
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer (2011) 1.36
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
Drug discovery: inhibitors that activate. Nature (2010) 1.22
Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat (2007) 1.21
Temporal control of Rac in Schwann cell-axon interaction is disrupted in NF2-mutant schwannoma cells. J Neurosci (2006) 1.17
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Sci Signal (2012) 1.13
Somatic instability of the NF2 gene in schwannomatosis. Arch Neurol (2003) 1.08
The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol (2002) 1.04
Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. Neurology (2006) 1.03
Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int J Cancer (2003) 1.02
Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine (2011) 0.98
Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet (2005) 0.96
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther (2013) 0.91
Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype. J Neurosurg (2006) 0.89
Neurofibromatosis 2 in the pediatric population. J Child Neurol (2003) 0.88
A role for the p53 pathway in the pathology of meningiomas with NF2 loss. J Neurooncol (2008) 0.88
Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov (2013) 0.85
Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A (2010) 0.84
SPRED proteins provide a NF-ty link to Ras suppression. Genes Dev (2012) 0.84
Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. Acta Neuropathol (2011) 0.83
Paths of resistance to EGFR inhibitors: is NF enough? Cancer Discov (2014) 0.82
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81
Patient and physician attitudes regarding clinical trials in neurofibromatosis 1. J Neurosci Nurs (2008) 0.79
Superficial neurofibromas in the setting of schwannomatosis: nosologic implications. Acta Neuropathol (2010) 0.76
Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J Clin Invest (2016) 0.75